FTC to Allow Tepezza Manufacturer to be Bought By Amgen Amid Growing Hearing Loss Litigation
The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
The deal seeks to prevent Amgen from leveraging its near-monopoly on Tepezza and other Horizon drugs into an overwhelming competitive advantage.
Acquiring Tepezza and Krystexxa would give Amgen a monopoly on those treatments, which it could then use to smother competition, the FTC warns
Most of the Uloric heart problems reported to the FDA were not on the warning label, researchers warn